The Case of Sara Monopoli: A Modern Tragedy

Key Insight

Sara Monopoli, 34 and pregnant, was diagnosed with inoperable, metastatic non-small cell lung cancer that had spread extensively, despite her healthy lifestyle and being a nonsmoker. After giving birth to her daughter Vivian, Sara and her husband, Rich, chose to pursue aggressive treatment, including multiple chemotherapy regimens, focusing on 'managing' the diagnosis rather than on survival statistics. Initial treatments included erlotinib, which caused severe side effects and proved ineffective due to her tumor's lack of a specific gene mutation.

Sara subsequently underwent various chemotherapy drugs, including carboplatin/gemcitabine and pemetrexed, all of which ultimately failed to stop the cancer's progression, leading to its spread to her liver, abdomen, and spine. Despite her underlying wish to die peacefully at home, Sara and her family remained in 'battle mode,' pursuing experimental therapies like a Pfizer drug (PF0231006) and further rounds of conventional chemotherapy (vinorelbine), even for a second, less aggressive thyroid cancer. She kept critical symptoms, such as double vision and numb hands, secret, fearing it would halt treatment.

In her final days, Sara was admitted to the hospital with pneumonia, her immune system compromised by aggressive therapies. Although her family had agreed against a breathing machine if her condition worsened, the default medical interventions persisted. Only after her primary care physician intervened, allowing for a palliative care team and morphine, was her suffering eased. Sara ultimately died at home, but her journey highlights how the relentless pursuit of treatment can override patient wishes and prolong distress when end-of-life discussions are inadequate or too late.